Mesoblast Limited (ADR) share price logo

Mesoblast Limited (ADR)

NASDAQ: MESO

Small Cap

$15.44

+0.61

(+4.11%)

as on

Mesoblast Limited (ADR) Stock Performance

as on July 13, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $15.24
    $15.72
    downward going graph

    1.30%

    Downside

    1.81%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $10.96
    $21.50
    downward going graph

    29.02%

    Downside

    39.25%

    Upside

    downward going graph

Mesoblast Limited (ADR) share price movements today

Previous Close
$14.83
Open
$15.63
Volume
445.4K
Day's Low - High
$15.24 - $15.72
52 Week Low - High
$10.96 - $21.50

Mesoblast Limited (ADR) Historical Returns

1 Month Return
+ 10.84 %
3 Month Return
+ 5.03 %
1 Year Return
+ 38.97 %
3 Year Return
+ 65.67 %
5 Year Return
+ 1.18 %

Mesoblast Limited (ADR) Stock Fundamentals & Key Indicators

Check Mesoblast Limited (ADR) market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.0B

EPS (TTM)

-0.49

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-64.3M

Revenue (TTM)

65.4M

Profit Margin

-144.33%

Return On Equity TTM

-18.22%

Mesoblast Limited (ADR) vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Mesoblast Limited (ADR) with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Mesoblast Limited (ADR) image
Mesoblast Limited (ADR)
BUY$2.0B1.18%NA-144.33%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$39.9B70.11%75.2512.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$123.2B144.74%28.8235.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$69.7B15.17%16.2429.65%0.54%

Stock Returns calculator for Mesoblast Limited (ADR) Stock including INR - Dollar returns

The Mesoblast Limited (ADR) stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Mesoblast Limited (ADR) investment value today

Current value as on today

₹1,54,086

Returns

₹54,086

(+54.09%)

Returns from Mesoblast Limited (ADR) Stock

₹38,974 (+38.97%)

Dollar Impact

₹15,112 (+15.11%)

Analyst Recommendation on Mesoblast Limited (ADR) Stock

Based on 9 analysts

BUY

77.78%

Buy

22.22%

Hold

0.00%

Sell

Based on 9 analysts, 77.78% of analysts recommend a 'BUY' rating for Mesoblast Limited (ADR). Average target price of $35

Mesoblast Limited (ADR) Share Price Target

Get share price movements and forecasts by analysts on Mesoblast Limited (ADR).

What analysts predicted

55.89%UPSIDE

Target Price

$35

Current Price

$15.44

Analyzed by

9 Analysts

Target

$35.00

Mesoblast Limited (ADR) target price $35, a slight upside of 55.89% compared to current price of $15.44. According to 9 analysts rating.

Indian Investors' Interest in Mesoblast Limited (ADR) Stock

Search interest for Mesoblast Limited (ADR) Stock has decreased by -20% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-20% versus previous 30 day period

Mesoblast Limited (ADR) Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
1
1
1
1
1
1
7
7
25
25
Gross Profit
-8
-8
-9
-9
-1
-1
-16
-16
-1
-1
Operating Income
-20
-20
-22
-22
-20
-20
-34
-34
-38
-38
EBITDA
-12
-12
-15
-15
-9
-9
-19
-19
-12
-12
Interest Expense
5
5
4
4
5
5
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-16
-16
-27
-27
-23
-23
-27
-27
-19
-19
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-16
-16
-27
-27
-23
-23
-27
-27
-20
-20
Net Profit Margin
-960.42%
-960.42%
-2204.34%
-2204.34%
-1518.82%
-1518.82%
-386.04%
-386.04%
-78.22%
-78.22%

Mesoblast Limited (ADR) Annual Profit & Loss

All numbers in Millions USD

Jun 2016
Jun 2017
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Total Revenue
42
2
17
16
32
7
10
7
5
17
Gross Profit
12
-9
11
-58
-49
-78
-53
-47
-35
12
Operating Income
-55
-90
-77
-80
-74
-109
-80
-69
-84
-62
EBITDA
-28
-87
-74
-84
-68
-84
-76
-58
-56
-73
Interest Expense
9
-
1
11
14
10
17
19
20
22
Depreciation
-
3
2
2
3
4
4
4
4
6
Income Before Tax
-90
-90
-65
-98
-87
-99
-91
-82
-88
-101
Income Tax Expense
-86
-13
-30
-8
-9
0
0
0
0
0
Net Income
-4
-76
-35
-89
-77
-98
-91
-81
-87
-102
Net Profit Margin
-9.70%
-3184.70%
-203.51%
-537.01%
-242.38%
-1325.25%
-894.59%
-1091.71%
-1490.27%
-593.92%

Mesoblast Limited (ADR) Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-27
-27
-23
-23
-27
-27
-
-
-
Operating Cash Flow
-11
-10
-10
-10
-12
-16
-14
-15
-4
Investing Cash Flow
0
0
0
0
0
0
0
0
0
Financing Cash Flow
11
-3
-1
-2
156
-4
-1
0
-4
Change in Cash
-1
-13
-11
-13
144
-20
-16
-14
-8

Mesoblast Limited (ADR) Annual Cash Flow

All numbers in Millions USD

Jun 2017
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Net Income
-76
-35
-89
-77
-98
-91
-81
-87
-102
Operating Cash Flow
-95
-75
-57
-56
-106
-65
-63
-48
-49
Investing Cash Flow
0
-1
-1
-3
-1
0
0
0
0
Financing Cash Flow
60
68
71
137
114
-9
74
40
147
Change in Cash
-35
-7
12
78
7
-76
10
-8
98

Global Institutional Holdings in Mesoblast Limited (ADR)

Funds
Holdings
Summit X, LLC
0.16%
Bank of America Corp
0.08%
Legal & General Group PLC
0.53%
LPL Financial Corp
0.04%
Two Sigma Investments LLC
0.03%
See all

Insights on Mesoblast Limited (ADR)

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -27.10M → -20.08M (in $), with an average increase of 17.5% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, MESO has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, MESO has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, MESO stock has moved up by 3.1%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 7 quarters, 1.25M → 25.67M (in $), with an average increase of 28.4% per quarter

About Mesoblast Limited (ADR)

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
OrganisationMesoblast Limited (ADR)
Headquarters55 Collins Street, Melbourne, VIC, Australia, 3000
IndustryBiotechnology
CEODr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
E-voting on sharesClick here to vote

Key Management of Mesoblast Limited (ADR)

Name

Title

Dr. Paul J. Simmons BSc, Ph.D.

Scientific Advisor to the Chief Executive Officer

Mr. Daniel Devine B.Sc., J.D., M.B.A

Head of Special Projects

Dr. Fiona See Ph.D.

Senior VP & Head of Translational Research

Mr. Marcelo Santoro

Chief Commercial Officer

Ms. Geraldine Storton B.Sc., M.B.A., MMS

Head of Regulatory Affairs & Quality Management

Mr. Justin Horst B.S.

Head of Manufacturing

Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)

Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director

Dr. Eric A. Rose M.D.

Chief Medical Officer & Executive Director

Mr. James Michael O'Brien CPA, M.B.A.

Chief Financial Officer

Mr. Paul Hughes BPHARM

Global Head of Corporate Communications & Joint Company Secretary

FAQs

What is Mesoblast Limited (ADR) share price today?

Mesoblast Limited (ADR) share price today is $15.44 as on at the close of the market. Mesoblast Limited (ADR) share today touched a day high of $15.72 and a low of $15.24.

What is the 52 week high and 52 week low for Mesoblast Limited (ADR) share?

Mesoblast Limited (ADR) share touched a 52 week high of $21.50 on and a 52 week low of $10.96 on . Mesoblast Limited (ADR) stock price today i.e. is closed at $15.44,which is 28.19% down from its 52 week high and 40.88% up from its 52 week low.

What is Mesoblast Limited (ADR)'s market capitalisation today?

Mesoblast Limited (ADR) market capitalisation is $0.00T as on .

How to invest in Mesoblast Limited (ADR) Stock (MESO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Mesoblast Limited (ADR) on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Mesoblast Limited (ADR) Shares that will get you 0.0972 shares as per Mesoblast Limited (ADR) share price of $15.44 per share as on July 13, 2026 at 8:46 am IST.

What is the minimum amount required to buy Mesoblast Limited (ADR) Stock (MESO) from India?

Indian investors can start investing in Mesoblast Limited (ADR) (MESO) shares with as little as ₹95.37 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹953.70 in Mesoblast Limited (ADR) stock (as per the Rupee-Dollar exchange rate as on ). Based on Mesoblast Limited (ADR) share’s latest price of $15.44 as on July 13, 2026 at 8:46 am IST, you will get 0.6477 shares of Mesoblast Limited (ADR). Learn more about fractional shares .

What are the returns that Mesoblast Limited (ADR) has given to Indian investors in the last 5 years?

Mesoblast Limited (ADR) stock has given 1.18% share price returns and 27.96% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?